[28, 29] Since RACs can suppress neuro-inflammation through upregulation of IL-10, it is plausible that RACs administration at 1 to 3 days after cerebral ischemia in mice would be associated with a favorable outcome. The gene discussed is IL10; the disease is brain ischemia.